Lantheus Q3 net income falls 19% to $22.4 million
LNTH•Lantheus reported third-quarter 2026 net income of $22.4 million, down 19%, while revenue rose to $389.9 million. The company also received FDA approvals for two products and said full-year guidance was suspended in connection with its pending merger with Curium.
1. Quarterly results
Lantheus’ third-quarter 2026 GAAP diluted earnings fell 20% to $0.33 per share, while revenue rose to $389.9 million. Neuraceq revenue more than doubled to $45.6 million, while PYLARIFY revenue declined to $238.9 million.
2. FDA approvals
The FDA approved Alzheimer’s imaging agent TAUKLARIFY and granted final approval for neuroendocrine tumor treatment BRAVNETSA.
3. Pending merger
The pending Curium merger offers $102.50 per share in cash and contingent value rights worth up to $12 per share. Lantheus suspended its full-year 2026 financial guidance in connection with the transaction.
